For patients with advanced-stage NSCLC being treated with concurrent chemoRT who miss treatment days secondary to acute toxicities, do you add on fractions at the end of treatment to compensate for repopulation, as is done in head and neck cancers?

It's a priority that patients undergoing definitive chemoradiation of any sort, especially inoperable NSCLC, not miss a fraction of RT. I encourage the continuation of RT in the setting of neutropenia, thrombocytopenia, and significant esophagitis, as long as reasonable and safe. Often the significa...